Investigation of the influence of anti-glaucoma eyedrops on the ocular surface
Not Applicable
Completed
- Conditions
- glaucoma
- Registration Number
- JPRN-UMIN000030246
- Lead Sponsor
- Inouye Eye Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 300
Inclusion Criteria
Not provided
Exclusion Criteria
1. Ocular surgery including laser therapy within 3 months. 2. History of corneal or conjunctival surgery. 3. History of glaucoma surgery. 4. History of surgery in thelacrimal drainage system. 5. History of contact lens use over 1 year. 6. Use of eyedrops other than anti-glaucoma eyedrops. 7. Existence of inflammatory disease in the anterior segment of the eye.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie anti-glaucoma eyedrops' effects on ocular surface epithelial cells?
How do beta-blockers and prostaglandin analogs compare in preserving corneal barrier function during glaucoma treatment?
What ocular surface biomarkers correlate with anti-glaucoma medication adherence and comfort in patients?
What are the long-term safety profiles of glaucoma eyedrops containing preservatives like benzalkonium chloride?
How do combination therapies with rho kinase inhibitors and anti-glaucoma agents affect tear film stability?